Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Marker Linked to Aggressive Prostate Cancer

By Biotechdaily staff writers
Posted on 29 May 2007
A recently identified genetic marker for prostate cancer is linked to a highly aggressive form of the disease. More...


This genetic marker ultimately will aid the development of a simple blood test to predict who is susceptible to this aggressive cancer. Knowing which patients carry this genetic marker also will guide doctors in how they treat the cancer.

A study, performed by Northwestern University's Feinberg School of Medicine (Chicago, IL, USA) investigators, showed a strong hereditary component to this aggressive cancer. Prostate cancer patients who carry the genetic marker--called 8q24--are much more likely to have a close family member with the disease. They have a 40% chance of having a close family member with prostate cancer. In contrast, prostate cancer patients who do not carry the marker have a 20% chance.

The study looked at more than 550 prostate cancer patients who had been treated at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Researchers wanted to identify the characteristics of prostate cancer in men who were carriers of these genetic markers to see if their cancer differed from that in men who did not carry the gene variant.

"We found the carriers of these 8q24 markers had more aggressive tumors,” said Prof. Helfand, an assistant research professor of urology at Northwestern's Feinberg School of Medicine, a co-principal investigator of the study and a physician at Northwestern Memorial Hospital. "Patients who were carriers had cancers that were more likely to spread into the lymph nodes and were more difficult to surgically remove.”

Dr. Helfand presented his findings on May 20, 2007, at the American Urological Association meeting in Anaheim, CA, USA.


Related Links:
Northwestern University's Feinberg School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.